Our study has demonstrated the efficacy of Kuzik® in the improvement of episodic MO with a reduction at
least of 50% in the frequency of attacks per month (51%) and in MIDAS disability score (84%). Kuzik®
was well tolerated and allowed a reduction of 50% of symptomatic drug assumptions in 43% of patients treated.
On the basis of these data, we suggest that the use of Kuzik® may have a role in the prophylactic treatment